Windlas Biotech Limited (WINDLAS.BO)
INR 966.75
(8.32%)
INR 966.75
(8.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.76 Billion INR | 39.12% |
| 2022 | 1.26 Billion INR | 31.66% |
| 2021 | 962.34 Million INR | -0.79% |
| 2020 | 970.04 Million INR | -24.7% |
| 2019 | 1.28 Billion INR | 23.17% |
| 2018 | 1.04 Billion INR | -36.55% |
| 2017 | 1.64 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -4.49 Billion INR | -355.25% |
| 2023 Q4 | 1.76 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.53 Billion INR | 0.0% |
| 2023 FY | 1.76 Billion INR | 39.12% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 1.26 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 1.26 Billion INR | 31.66% |
| 2022 Q2 | 1.09 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 962.34 Million INR | -0.79% |
| 2021 Q4 | 962.34 Million INR | 0.0% |
| 2021 Q2 | 919.1 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 970.04 Million INR | -24.7% |
| 2020 Q4 | 970.04 Million INR | -21.07% |
| 2020 Q3 | 1.22 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 1.28 Billion INR | 0.0% |
| 2019 FY | 1.28 Billion INR | 23.17% |
| 2018 FY | 1.04 Billion INR | -36.55% |
| 2017 FY | 1.64 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.04% |
| NATCO Pharma Limited | 10.53 Billion INR | 83.263% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 13.348% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -51.277% |
| Achyut Healthcare Limited | 2.01 Million INR | -87465.822% |
| Ajanta Pharma Limited | 10.71 Billion INR | 83.542% |
| Alkem Laboratories Limited | 48.6 Billion INR | 96.373% |
| Alpa Laboratories Limited | 307.12 Million INR | -473.941% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 89.168% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 51.853% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.842% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 63.788% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 16.414% |
| Brooks Laboratories Limited | 248.6 Million INR | -609.048% |
| Divi's Laboratories Limited | 18.99 Billion INR | 90.718% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.352% |
| Eris Lifesciences Limited | 38.26 Billion INR | 95.394% |
| FDC Limited | 3.7 Billion INR | 52.478% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.293% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 65.977% |
| Granules India Limited | 22.95 Billion INR | 92.321% |
| Gufic Biosciences Limited | 5.59 Billion INR | 68.522% |
| Hester Biosciences Limited | 3.59 Billion INR | 50.964% |
| Indoco Remedies Limited | 10.34 Billion INR | 82.956% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 23.008% |
| Ipca Laboratories Limited | 33.74 Billion INR | 94.776% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -493.982% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 40.728% |
| Lasa Supergenerics Limited | 541.92 Million INR | -225.266% |
| Laurus Labs Limited | 42.71 Billion INR | 95.873% |
| Lupin Limited | 96.23 Billion INR | 98.168% |
| Mankind Pharma Limited | 23.87 Billion INR | 92.617% |
| Medicamen Biotech Limited | 940.36 Million INR | -87.448% |
| Medico Remedies Limited | 438.24 Million INR | -302.219% |
| Megasoft Limited | 1.85 Billion INR | 4.881% |
| Piramal Pharma Limited | 74 Billion INR | 97.618% |
| RPG Life Sciences Limited | 1.38 Billion INR | -27.713% |
| Sigachi Industries Limited | 2.53 Billion INR | 30.363% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 54.72% |
| Unichem Laboratories Limited | 8.06 Billion INR | 78.155% |
| Wanbury Limited | 3.15 Billion INR | 44.139% |
| ZIM Laboratories Limited | 2.08 Billion INR | 15.286% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 97.545% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 31.177% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -124.885% |
| Bal Pharma Limited | 2.51 Billion INR | 29.809% |
| Strides Pharma Science Limited | 37.68 Billion INR | 95.322% |
| Venus Remedies Limited | 1.39 Billion INR | -26.558% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 78.636% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 84.287% |
| Shilpa Medicare Limited | 12.93 Billion INR | 86.37% |
| Aarti Drugs Limited | 11.5 Billion INR | 84.678% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 72.148% |
| Suven Life Sciences Limited | 148.62 Million INR | -1086.037% |
| Ind-Swift Limited | 13.45 Billion INR | 86.897% |
| Valiant Laboratories Limited | 1.05 Billion INR | -66.566% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 83.538% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 87.537% |
| Themis Medicare Limited | 1.88 Billion INR | 6.612% |
| Hikal Limited | 12.99 Billion INR | 86.435% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.852% |
| Sequent Scientific Limited | 8.27 Billion INR | 78.697% |
| Novartis India Limited | 1.8 Billion INR | 2.132% |
| Wockhardt Limited | 39.87 Billion INR | 95.579% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 97.123% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -510.355% |
| Neuland Laboratories Limited | 5.49 Billion INR | 67.943% |
| Morepen Laboratories Limited | 4.45 Billion INR | 60.476% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -173.761% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 10.809% |